PD-L1 Testing German Experience. P. Schirmacher for QuIP
|
|
- Sharleen Charles
- 5 years ago
- Views:
Transcription
1 PD-L1 Testing German Experience P. Schirmacher for QuIP
2 Quality Management Molecular Diagnostics Method/Inter-Center-Optimisation/Validation Preclinical Validation/internal QM Accreditation Institutes (DAkkS; ISO 9001 DIN 17020) National Round Robins (QuIP)
3 QuiP (DGP) Independent Self administered Non commercial Expert guided (Panels) Extensive RR-Expertise (> 300 RRs) High acceptance (diagnostic community, clinicians, industry, politics) International (in selected indications) ESP-LOA and cooperation
4 Principle: Free Choice of Methods Free Choice of Method, e.g. Sanger Pyro-Sequencing Mutation-spezifische PCR NGS (Deep/Panel Sequencing) Reflection of technology Evaluation by diagnostic result
5 Constant Round Robins RfB BRAF 600 BRAF 600 BRAF 600 BRAF 600 RfB CD117 CD117 CD117 CD117 CD117 CD117 CD117 CD117 RfB EGFR EGFR EGFR RfB Erez/PRez Erez/PRez Erez/PRez Erez/PRez Erez/PRez Erez/PRez Erez/PRez RfB GIST GIST GIST GIST GIST RfB HER2n IHC HER2n IHC HER2n IHC HER2n IHC HER2n IHC RfB HER2n ISH HER2n ISH HER2n ISH HER2n ISH HER2n ISH RfB Keratine Keratine Keratine Keratine Keratine Keratine Keratine Keratine RfB KlonML KlonML KlonML KlonML KlonML KlonML KlonML RfB KRAS RfB Lymphome Lymphome Lymphome Lymphome Lymphome Lymphome Lymphome Lymphome RfB MMRD MMRD MMRD MMRD MMRD MMRD MMRD MMRD RfB MSI MSI MSI MSI MSI MSI MSI RfB NEM NEM NEM NEM NEM NEM NEM NEM RfB RAS RAS RAS RAS multiblock ER ER ER ER ER ER ER ER multiblock PR PR PR PR PR PR PR PR multiblock Her2-IM Her2-IM Her2-IM Her2-IM Her2-IM Her2-IM Her2-IM Her2-IM multiblock Her2-ISH Her2-ISH Her2-ISH Her2-ISH Her2-ISH Her2-ISH Her2-ISH Her2-ISH multiblock Ki-67 Ki-67 Ki-67 Ki-67 Ki-67 Ki-67 Ki-67 Ki-67 provitro HPV HPV HPV HPV HPV HPV HPV HPV provitro TBc TBc TBc TBc TBc TBc TBc TBc RfB T790M T790M RfB PD-L1MM RfB PD-L1 NSCLC PD-L1 NSCLC EGFR IHC RfB sqnsclc RfB BRCA1/2 BRCA1/2 RfB BRAF 600 Lunge
6 Prototypic Round Robins Round Robin Status Round Robin Status T790M 2016 PD-L1 NSCLC EGFR IHC sqnsclc PD-L1 Melanoma (2) finished final report final report final report MLH1 ROS1 IDH1(R132H) Consideration QuIP-Board Consideration QuIP-Board Consideration QuIP-Board T790M 2017 (2) ongoing Q1-Q2 PD-L1 NSCLC (2) ongoing Q1-Q2 BRAF V600 (2) BRCA 1/2 (2) planned Q3-Q4 planned Q3-Q4
7 Implementation of new Diagnostic Assays Information about approval of new drug with predictive molecular testing (1-3 months ahead) Implementation Validation and optimisation of testing modalities Solutions for open scientific issues Diagnostic recommendations, information, discussion with clinical societies Diagnostics for early accession/ compassionate use programs Broad/nationwide availability (methodology, expertise, training) Agreement on reimbursement issues Local issues Others (e.g. legal issues) Quality Management Panel-establishment and -validation (> 3 m) Establishment of expert panel (n~5-8; Lead- Institutes; other Panel centers) Consent about approach (methodology, time schedule, testing conditions etc.) Identification and selection of suitable test cases Cross validation by lead institutes Testing/validation of panel centers; evaluation; set-up of RR conditions National/international round robin (> 2 m) announcement/feed-back; application preparation by Lead-institutes, RfB Probe mailing, testing, test results mailed Evaluation and publication Implementation without regulatory, financial and intellectual framework but decisive for drug/therapy success (system relevant). Requires Competence Center System (Peers) and more attention by industry and regulatory authorities
8 PD-L1 IHC German Strategy for Roll-out and QM National Harmonisation Study (DGP) Validation Harmonisation Recommendation National QA Measures (QuIP) Quality Assurance Teaching and Training National Improvement Activity (nngm/dkh)
9 PD-L1 IHC in NSCLC National Harmonisation-Study Pathology: Reinhard Büttner Manfred Dietel Lukas Heukamp Korinna Jöhrens Thomas Kirchner Simone Reu Josef Rüschoff Andreas Scheel Hans-Ulrich Schildhaus Peter Schirmacher Markus Tiemann Arne Warth Wilko Weichert Industrial Partners BMS MSD Roche AstraZeneca Ventana Dako Targos
10 Response to Anti PD-1 (Pembrolizumab) and Expression of PD-L1 in NSCLC
11 Different Antibodies and Antibody Reactivities Scheel et al., 2016
12 Tumorimmunotherapy: PDL-1-Testing
13 BIRCH: PD-L1 TC and IC Selection Criteria TC2/3 IC2/3 Intrinsic PD-L1 expression in tumor cells (TC) 34% of screened patients between Jan and Dec Adaptive PD-L1 expression in tumor-infiltrating immune cells (IC) BIRCH enrolled patients with tumors that were PD-L1 TC2/3 or IC2/3 VENTANA SP142 IHC assay was used to determine PD-L1 expression on both TC and IC Archival or freshly collected tumor specimens were required for PD-L1 testing at a central laboratory PD-L1 as a predictive biomarker: PD-L1 expression on TC and IC was independently predictive of response in patients with previously treated NSCLC (i.e., POPLAR) 1,2 TC3 or IC3 = TC 50% or IC 10% PD-L1+ cells; TC2/3 or IC2/3 = TC or IC 5% PD-L1+ cells, respectively. 1. Horn L, et al. ASCO 2015; 2. Vansteenkiste J, et al. ECC Besse et al, Oral Presentation at ECC 2015
14 A Global NSCLC-PDL1 Score? Scheel et al., 2016
15 Interobserver-Validation (Phase I) Scheel et al., 2016
16 Harmonisation Study: Immune Cells Scheel AH et al., Modern Pathology 2016
17 Phase 2 Assays: - Performance in multiple Institutes / Reliability - Staining pattern - validation of Phase 1; fixed assay vs. open protocol - Inter-lab concordance Evaluation: - Validation proportional score (6-step) - Local vs. central evaluation
18 Phase 2 Targos Molecular Pathology; - Project management Phase 2 - NSCLC-TMAs (project specific): - 'TMA-Master' (3DHistotech) mm cores - Central provision of slides 8 Pathology Institutes - Trial analog protocols Dako 22C3, 28-8 Ventana SP142, SP263 - Open protocol: 22C3, 28-8 (local protocols) - 3 institutes per protocol
19 PD-L1 Testing + Robust, broadly available technology (IHC) Good antibodies; alternatives exist Robust, relatively stable assay Consented algorithm - Stand-alone assay/ no methodical convergence Singular analyses Algorithm/reporting complexity; dynamic Heterogenous expression; 1% threshold problematic Insufficient refunding
20 Prototypic Round Robin PD-L1-NSCLC (1) Decision for RR, Lead- and Panel Institutes 6.16 Coordination of Lead Institutes, selection of cases, trilateral validation Testing of the Panel Institutes (internal RR) Evaluation of internal RRresults, Lead/Panel-Institute; meeting, decision for open RR 15.9 Public PD-L1 training meeting (Charite) End of 9.16 Open RR Lead Institutes: Berlin, Cologne, Göttingen Panel Institutes: Hannover, Heidelberg, Jena, Munich TU, Munich LMU Composition: 10 cases; 2 points each, 18 points necessary for certificate No methodical restriction, sections provided Optional reporting of methodology Option to challenge and for educational
21 Prototypic Round Robin Participants: 83 (76 D, 4 A, 3 CH) Successful: 60 Success rate: 72% PD-L1-NSCLC (1) Composition < 1%: 3 cases 1%-49%: 2 cases %: 5 cases
22 PD-L1-NSCLC Round Robin Antibodies
23 PD-L1-NSCLC Challenge Challenged result: 18 Institutes 1 Institute post hoc success 4 Institutes: Interpretation problems 13 Institutes: Staining problems
24 Prototypic Round Robin Malignant Melanoma (1) 3.8 Panel-Institutes.16 Decision for RR Decision on Lead- and Panel Institutes 9/10.16 Coordination of Lead Institutes, Case selection and reciprocal testing Testing of Panel Institutes (internal RR) 9/10 Announcement of open RR open RR Evaluation of open RR; announcement of results Lead Institutes: Berlin, Heidelberg, TU Munich Panel Institutes: Hannover, Munich LMU, Cologne, Hamburg, Göttingen, Würzburg Composition: 10 cases; 2 points each, 18 points necessary for certificate No methodical restriction, sections provided Optional reporting of methodology Option to challenge and for educational
25 Prototypic Round Robin PD-L1-Melanoma Participants: 44 Successful: 37 Success rate: 84% Composition <5%: 5 cases >5%: 5 cases
26 PD-L1-Melanoma Round Robin Antibodies
27 PD-L1-NSCLC and MM Round Robin Other Conclusions Diverse use of primary antibodies 28-8 and SP263 stain stronger 22C3 stains rather weaker Discrepancies are rather towards lower staining intensities Establishment using tonsil tissue suggested
28 Future and Ongoing Activities PD-L1-NSCLC (2) ongoing (until 15.5.) PD-L1 Bladder Cancer in preparation PD-L1 MM (2) in discussion
29 Other/Better Markers!? PD-L1 Gene CNV/expression MSI Mutational load Immunophenotyping Combinations RESISTANCE MARKERS
30 PD-L1 Amplifications/Deletions and/or Mutational Load Increasing number of mutations n=78 n=40 WGS/WES? Panels? Others? Budczies et al. 2016
31 Immune Cell Infiltration and Response to Conventional and Personalized Treatment Lasitschka, F, Schirmacher P, Jäger D, Halama N, et al.
32
33
34 Constant Round Robins Participants 2016 Participants 2016 RR RR BRAF 58 ER 186 CD PR 177 GIST 39 Her2-IM 198 Her2nlHC 88 Her2-ISH 103 Her2nlSH 52 Ki RAS 71 Lymphone 71 HPV 7 MMRD 84 TBC 14 MSI 45 Keratine 88 KlonML 29 NEM 69 EGFR 48
Quality control of PD-L1 in NSCLC - Results of two German ring trials Dr. Andreas Scheel University Hospital Cologne
Quality control of PD-L1 in NSCLC - Results of two German ring trials 2017-06-07 Dr. Andreas Scheel University Hospital Cologne Step-wise approach Predictive value Biological significance Technical aspects
More informationSantiago de Chile, September 6 th, 2018
Reinhard Buettner Institute for Pathology CIO Cologne Bonn www.ngm-cancer.com Innovative Biomarkers and Immune Profiling: PD-L1, TMB, and other protein immunohistochemistry. 1506LA1805193-01 Santiago de
More informationNSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA
Lung cancer and other malignancies -PD-L1 assay, QuIP EQA Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP 11.05.2018 NSCLC Harmonization
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationCorporate presentatie Maastricht UMC+ (titel presentatie)
Datum Corporate presentatie Maastricht UMC+ (titel presentatie) PDL1: een simpele kleuring? Titel Naam spreker van (optioneel) de presentatie Functie spreker (optioneel) Onderwerpregel Ernst Jan M. Speel,
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationImmunotherapy in NSCLC Pathologist role
Immunotherapy in NSCLC Pathologist role Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in NSCLC Khono et al, Trans Lung
More informationSabrina Schmitt: "German Biobank Node s concept for quality management"
Sabrina Schmitt: "German Biobank Node s concept for quality management" German Biobank Node s concept for quality management S. Schmitt K.-F. Becker, B. Meinung, E. Herpel, J. Slotta-Huspenina Sep-14-2016,
More informationHSL-Advanced Diagnostics 2018 / 19 Test & Service List
HSL-Advanced Diagnostics 2018 / 19 Test & Service List 2018/19 TEST & SERVICE LIST Haematoxylin & Eosin H&E H&E per slide Routine Immunohistochemistry Immunohistochemical demonstration of an antigen in
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationBiomarkers for Cancer Immunotherapy Debate
Biomarkers for Cancer Immunotherapy Debate Moderator: Maria Karasarides, PhD AstraZeneca Pro: Daniel S. Chen, MD, PhD Genentech Con: Steve Averbuch, MD Bristol-Myers Squibb Biomarkers to Select Patients
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationCarcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos
Carcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background Immunotherapy
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationOverview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories
Overview of the ESP Lung and Colon EQA schemes with a focus on Dutch laboratories Dr. Nils t Hart University Medical Center Groningen, The Netherlands Drs. Cleo Keppens Catholic University of Leuven, Belgium
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationDisclosures. Molecular Cytopathology. Update on Molecular Testing of Cytology Specimens: Beyond the Cell Block. Molecular Cytopathology Solid Tumor
Update on Molecular Testing of Cytology Specimens: Beyond the Cell Block Disclosures None relevant to this talks Dara L. Aisner, M.D., Ph.D. Assistant Professor Co-Director, Colorado Molecular Correlates
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationLearning from the Impact of the Drug-Diagnostics Strategy in Oncology
Learning from the Impact of the Drug-Diagnostics Strategy in Oncology Critical Path to TB Drug Regimens 2017 Workshop Washington DC March 22, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute
More informationCompanion & Complementary Diagnostics: Clinical and Regulatory Perspectives
Companion & Complementary Diagnostics: Clinical and Regulatory Perspectives Workshop on Companion Diagnostics January 31, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute Fredensborg, Denmark
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationTITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma
TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1 Immunohistochemistry in Non-Small Cell Lung Carcinoma Ms Amy Newman, Ms Suzanne Parry, Mrs Dawn Wilkinson, Dr Tony O Grady, Dr Perry Maxwell, Mr David
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationMolecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018
Molecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018 Some Key Points Molecular Testing has applications in every section
More informationQuantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationQuality Indicators - Anatomic Pathology- HSC/STC Jul-Sep 2 nd Qtr. Apr-Jun 1 st Qtr
Eastern Health Volume 86 Page 001 CIHRT Exhibit P-3595 Page 1 INDICATOR Financial Overtime Hours / FTE Workload Increase - FTE equivalent Workload Quality Indicators - Anatomic Pathology- HSC/STC TOTAL
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationData Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis
February, 13th 2018 Data Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies:
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationInnovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1
Innovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1 Monday, October 17, 2016 MaRS Discovery District, Toronto This session was generously sponsored by Merck Canada
More informationBreast cancer pathology
Breast cancer pathology Giancarlo Pruneri, M.D. National Cancer Institute (INT) Milan University of Milan, School of Medicine Giancarlo.Pruneri@unimi.it Currently accepted prognostic/predictive parameters
More informationHow could molecular profiling impact histology independent labels in the future?
How could molecular profiling impact histology independent labels in the future? Marlene Thomas Senior international scientific director for personalised healthcare F. Hoffman-La Roche Ltd The information
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More informationColon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP
Colon cancer: practical molecular diagnostics Wade S. Samowitz, M.D. University of Utah and ARUP Disclosure Dr. Samowitz may receive royalties in the future related to the Ventana BRAF V600E antibody.
More informationOverview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade
Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade David L. Rimm MD-PhD Professor Departments of Pathology and Medicine (Oncology) Director, Yale Pathology Tissue Services Disclosures
More informationRoche Pharma Day 2015
Roche Pharma Day 2015 Molecular Information Garret Hampton VP, Oncology Biomarker Development Pharmaceuticals Division Personalized healthcare A cornerstone of the Genentech / Roche strategy Diagnostics
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationLung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More informationHistoCyte Laboratories Ltd
HistoCyte Laboratories Ltd Progesterone Receptor: The neglected breast receptor! Dr Ian Milton & Colin Tristram November 2018 UKNEQAS Autumn meeting Introduction Progesterone is an important prognostic
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationIDH1 R132H/ATRX Immunohistochemical validation
IDH1 R132H/ATRX Immunohistochemical validation CIQC/DSM 2016 12 June 2016 0835-0905 Stephen Yip, M.D., Ph.D., FRCPC University of British Columbia Disclosure Statement I have nothing to disclose I will
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationInfrastructure for Clinical Data Exchange
Infrastructure for Clinical Data Exchange Amy Abernethy, MD, PhD FEBRUARY 29 2016 Instrument Data Highly Structured Administrative Data Highly Structured Clinical Research Data Intentionally Structured
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More information21 st Century Slide Based Pathology & Molecular Diagnostics: From the Laboratory to the Patient
A meeting hosted by UK NEQAS ICC & ISH at The Tower Hotel Conference Centre St Katharine's Way, London E1W 1LD 21 st Century Slide Based Pathology & Molecular Diagnostics: From the Laboratory to the Patient
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationAndreas Wicki. University Hospital Basel Switzerland
Andreas Wicki University Hospital Basel Switzerland Disclosures Funding of research projects: Piqur Therapeutics Consultancy: Actelion Pharmaceuticals Predictive Biomarkers for Targeted Therapy in Oncology
More informationNGS in Lung Cancer Cytology
Institute of Pathology NGS in Lung Cancer Cytology Spasenija Savic University Hospital Basel, Switzerland Disclosures Speakers honoraria and advisory boards: Astra Zeneca, BMS, MSD, Novartis, Pfizer, Roche
More informationInnovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015
Innovation and value creation Severin Schwan, CEO Roche Group Zurich, January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words
More informationEmerging biomarkers for immunotherapy in lung cancer
Emerging biomarkers for immunotherapy in lung cancer Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Aberdeen, UK Why Do We Need Biomarkers for Immunotherapy?
More informationHow close are we to standardised extended RAS gene mutation testing? The UK NEQAS experience
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS experience Dr Susan D. Richman, Dr Jennifer Fairley, Dr Rachel Butler, Dr Zandra C. Deans Overview Introduction to UK NEQAS
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationAgilent companion diagnostics for cancer immunotherapy
Agilent companion diagnostics for cancer immunotherapy Annika Eklund, PhD Global Product Manager Companion Diagnostics Agilent Technologies Aalborg 1 Agilent Trusted Answers. Together OUR FOCUS life sciences,
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationValida5on of a Microsatellite Instability Assay by NGS
Valida5on of a Microsatellite Instability Assay by NGS Mark R. Miglarese, Ph.D. VP R&D 1 Caris Life Sciences 230,000+ tests performed in 2016 Headquarters: Irving, Texas Laboratory: Phoenix, Arizona 66,000
More informationClinical Utility of Diagnostic Tests
Clinical Utility of Diagnostic Tests David A. Eberhard MD, PhD Director, Pre-Clinical Genomic Pathology, Lineberger Comprehensive Cancer Center Associate Professor, Depts. of Pathology and Pharmacology
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationTechnology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy Technology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520 NICE 2018. All rights
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes 1 Idylla : easy, rapid and accurate molecular medicine for every patient Paola Valente Strategic Marketing Biocartis 6th meeting on external quality assessment
More informationClinical Utility of Actionable Genome Information in Precision Oncology Clinic
Indian Ocean Rim 2017 Laboratory Haematology Congress 2017. 6.18-19, Singapore Clinical Utility of Actionable Genome Information in Precision Oncology Clinic Reimbursement program for NGS panel tests in
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More information